• BV6 IAP Antagonist: Cancer Research Workflows

  2026-08-20

  BV6 is a Smac mimetic IAP antagonist for probing apoptosis, therapy sensitization, and immune-mediated cytotoxicity in cancer models. This workflow-led guide connects dose preparation, time-resolved readouts, radiosensitization studies, and the reference study’s caution against relying on a single cell-death marker.

• KCNE4 Modulation of Kv1.3 Blocker Pharmacology

  2026-08-20

  The reference study shows that the leukocyte ancillary subunit KCNE4 changes the inhibition kinetics of Kv1.3 by the intracellular blocker Psora-4 without measurably changing blocker affinity. Its findings establish channel-complex architecture, not only pore-forming subunit identity, as a critical variable in pharmacological studies of immune Kv1.3.

• SN-38 Beyond TOP1: A Translational Roadmap

  2026-08-19

  7-Ethyl-10-hydroxycamptothecin, also known as SN-38, offers translational researchers a way to study DNA topoisomerase I trapping alongside FUBP1–FUSE disruption. This article connects mechanism, model selection, assay design, and research-use strategy for advanced colon cancer research while distinguishing established evidence from testable hypotheses.

• LINC02870 Drives SNAIL Translation in HCC

  2026-08-19

  The reference study identifies LINC02870 as a potentially oncogenic lncRNA in hepatocellular carcinoma and links it to EIF4G1-dependent enhancement of SNAIL translation. Its integrated expression, prognosis, interaction, and cell-phenotype analyses provide a mechanistic framework for studying how noncoding transcripts influence metastatic behavior, particularly in HBV-associated disease.

• Dinaciclib and the Mechanics of Tissue Boundaries

  2026-08-18

  Dinaciclib (SCH727965) is more than a potent CDK inhibitor for cell-cycle and apoptosis studies. This article examines how its multi-CDK activity can be used to test the mechanical consequences of cell division while separating boundary remodeling from cytotoxicity.

• Sodium-Driven Mitochondrial Failure in NECSO

  2026-08-18

  Qiao and colleagues identify mitochondrial energy failure as a central execution mechanism in sodium-overload necrosis (NECSO), linking TRPM4-mediated Na+ entry to NCLX-dependent mitochondrial ion imbalance, suppressed oxidative phosphorylation, and ATP depletion. The findings provide a mechanistic framework for studying how ion dysregulation collapses cellular energy maintenance and causes swelling and lysis.

• Difloxacin HCl in Resistance Research

  2026-08-17

  Difloxacin HCl supports two distinct bench applications: antimicrobial susceptibility testing through bacterial DNA replication inhibition and cell-based studies of multidrug resistance reversal. This guide translates its chemistry and the p31comet–Plk1 checkpoint findings into practical workflows, controls, and troubleshooting decisions.

• N-Formimidoyl Thienamycin vs. Cefoperazone

  2026-08-17

  The 1982 study by Cullmann and colleagues compared N-formimidoyl thienamycin (MK0787) with several newer β-lactam antibiotics across a broad panel of resistant clinical isolates. Its central contribution was to pair MIC comparisons with bactericidal and β-lactamase-related analyses, revealing particularly strong activity against Pseudomonas aeruginosa, Acinetobacter spp., and diverse gram-negative bacilli.

• Perifosine: Akt Signaling as a Causal Assay Probe

  2026-08-16

  Perifosine (KRX-0401) is examined here as more than an apoptosis reagent: it is a mechanistic perturbation tool for testing Akt-linked stress responses. The article connects oncology evidence with the PEDF–PI3K/Akt/mTOR framework reported in cerebral ischemia/reperfusion research while defining the limits of that cross-domain interpretation.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-08-15

  The reference study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-dependent mitotic checkpoint complex disassembly. By combining HeLa cell extracts, purified proteins, phosphosite analysis, and an S102A mutant, the authors show how Plk1 phosphorylation can prevent premature checkpoint inactivation and reduce futile MCC cycling.

• CUX2 Neuron Loss and DNA Damage in Neuroinflammation

  2026-08-14

  The reference study identifies DNA damage burden and inadequate double-strand break repair as drivers of selective CUX2-positive layer 2/3 excitatory neuron loss during neuroinflammation. Its combination of human multiple sclerosis tissue, mouse inflammatory models, genetic perturbation, and interferon-γ experiments links neuronal vulnerability to a defined stress-response and repair axis.

• Cell Cycle Assay Kit for CRC Response Profiling

  2026-08-14

  Use PI-based DNA-content profiling to connect colorectal cancer treatment responses with G0/G1, S, and G2/M redistribution. This workflow pairs the Cell Cycle Assay Kit with apoptosis readouts and metabolic studies to clarify how CGF-associated stress affects proliferation without overstating what DNA content alone can prove.

• Mianserin HCl: Findings from a Controlled Trial

  2026-08-13

  The reference paper evaluated mianserin hydrochloride against amitriptyline using blinded clinical ratings, systematic side-effect monitoring, and serial plasma drug measurements. It found broadly similar antidepressant efficacy, fewer recorded adverse effects with mianserin, and no clear relationship between plasma mianserin concentration and therapeutic response.

• Fludarabine Workflow for DNA Synthesis Studies

  2026-08-13

  Build a reproducible Fludarabine workflow that connects DNA replication stress with cell-cycle arrest and apoptosis readouts. Practical dosing, solubility control, genotype-aware design, and troubleshooting make it useful for leukemia research, multiple myeloma research, and translational assay development.

• MSNs@SF-HA-FA Targets NSCLC Metastasis

  2026-08-12

  Li et al. identify an SPI1/miR-616-5p regulatory axis that promotes non-small cell lung cancer invasion and migration, and show that sulforaphane can inhibit this pathway. A hyaluronic acid- and folic acid-modified mesoporous silica nanoparticle system improves sulforaphane stability, uptake, tumor targeting, and anti-metastatic activity in NSCLC xenograft models.

16000 records 1/1067 page Next 12345 下5页 Last page